Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02068625
Other study ID # 178/10
Secondary ID 2012DR2022
Status Terminated
Phase Phase 4
First received
Last updated
Start date September 2010
Est. completion date December 31, 2018

Study information

Verified date February 2019
Source University Hospital Inselspital, Berne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomised, double-blind, placebo-controlled clinical trial investigates the neuroprotective effect of rasagiline in patients suffering from a retinal detachment affecting central vision. Based on results from a study in mice suffering from retinal degeneration, the investigators hypothesize that rasagiline delays neurodegeneration in the retina and improves visual acuity outcomes after retinal detachment surgery. Rasagiline is a second-generation propargylamine with neuroprotective properties modulating the caspase-dependent pathway of programmed cell death.


Description:

Background

In previous experimental studies neuroprotection by rasagiline has been shown in rds-mice, a model for slow retinal degeneration. It is known from these experiments that rasagiline specifically delays apoptosis, but also modifies inflammation and autophagy. The bioavailability of the drug in the central nervous system is high, and based on the literature is sufficient in the retina.

In retinal detachments the outer layers of the neurosensory retina are deprived of nutrients and degeneration of the photoreceptors occurs fast. This is particularly relevant in the macular area of the retina where the density of photoreceptors is high, such that visual acuity recovery can be significantly limited by photoreceptor loss.

Objective

To assess the neuroprotective effect of oral rasagiline (1mg daily for 7 days) administered perioperatively in patients undergoing surgical retinal detachment repair for central vision involving retinal detachments.

Methods

In this clinical trial, patients suffering from retinal detachments affecting the fovea get randomly assigned to perioperative oral treatment with either rasagiline (1mg) or placebo once daily for 7 days. Pharmacologic treatment is initiated at the time of hospital admission, usually the day before surgery. The main outcome of the study is visual acuity six months after surgical retinal detachment repair. Structural differences of the neurosensory retina between groups will be analysed by optical coherence tomography, a non-invasive imaging method for retinal pathology.


Recruitment information / eligibility

Status Terminated
Enrollment 23
Est. completion date December 31, 2018
Est. primary completion date December 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Rhegmatogenous retinal detachment

- Central vision affected for less than 72 hours

- Pseudophakic

- Age 18 or over

- Not participating in other clinical trials

- Willing to attend follow-up visits

- Written informed consent

Exclusion Criteria

- Phakic

- Narrow angle glaucoma

- Previous intraocular surgery other than cataract operation

- Retinal disease

- Concurrent treatment with MAO inhibitors

- Pregnancy

- Malignant arterial hypertension

- Liver or kidney failure

- Life-threatening or malignant disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rasagiline
Rasagiline 1mg daily orally for 7 days
Placebo
Oral treatment with placebo for 7 days

Locations

Country Name City State
Switzerland Department of Ophthalmology, Bern University Hospital Bern

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

References & Publications (5)

Cook B, Lewis GP, Fisher SK, Adler R. Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci. 1995 May;36(6):990-6. — View Citation

Eigeldinger-Berthou S, Meier C, Zulliger R, Lecaudé S, Enzmann V, Sarra GM. Rasagiline interferes with neurodegeneration in the Prph2/rds mouse. Retina. 2012 Mar;32(3):617-28. doi: 10.1097/IAE.0b013e31821e2070. — View Citation

Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm (Vienna). 2005 Aug;112(8):991-1003. Epub 2005 Mar 15. — View Citation

Travis GH. Mechanisms of cell death in the inherited retinal degenerations. Am J Hum Genet. 1998 Mar;62(3):503-8. Review. — View Citation

Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary ETDRS Visual Acuity 6 months
Secondary Central retinal thickness Measured by Optical Coherence Tomography (OCT) 6 months
Secondary Number of patients with side effects 6 months
See also
  Status Clinical Trial Phase
Completed NCT03332758 - Inflammasomes in Cell Death in FTMH, ERM, and RRD
Completed NCT03660384 - Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT04535622 - Efficacy of Exercise Program for Facedown Posture-related Pain After Retinal Surgery N/A
Recruiting NCT05863312 - REtinal Detachment Outcomes Study N/A
Recruiting NCT05561569 - Air Versus Gas Tamponade in Primary Retinal Detachment N/A
Not yet recruiting NCT05538156 - Internal Limiting Membrane Peeling in Retinal Detachment Surgery N/A
Completed NCT03046719 - Subconjunctiva Bupivacaine as Analgesia in Intravitreal Silicone Oil Removal N/A
Recruiting NCT01261533 - Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment Phase 1
Completed NCT00000140 - The Silicone Study Phase 3
Recruiting NCT05543018 - Effect of Intraocular Tamponade on Visual Perception N/A
Not yet recruiting NCT04518696 - Suprachoroidal Buckling for the Management of Rhegmatogenous Retinal Detachment N/A
Completed NCT03321253 - Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification N/A
Completed NCT06166914 - Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment N/A
Enrolling by invitation NCT05566626 - Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera N/A
Not yet recruiting NCT03631108 - Feasibility Study and Preliminary Application Study on Iris OCTA
Recruiting NCT02201706 - Multi-electrocoagulation Retinectomy for Retinal Re-detachment in Silicone Oil Filled Eye N/A
Completed NCT03218371 - Scleral Self-indentation Chandelier-assisted Peripheral Vitrectomy Under Air Rhegmatogenous Retinal Detachment. N/A
Completed NCT00000154 - Diabetic Retinopathy Vitrectomy Study (DRVS) Phase 3
Recruiting NCT05583253 - Visual Outcome of Vitrectomy After Refractive Surgery N/A